Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of HC010 as first-line treatment for PD-L1-positive advanced non-small cell lung cancer
CTR20253449Phase 2Active
- Sponsor
- Shanghai Hongcheng Pharmaceutical Co. Ltd.
- Start
- Oct 2025
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HC010 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Hongcheng Pharmaceutical Co. Ltd.. Started Oct 2025; status: active.
02
Drugs
HC010
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253449.